

Value-Based Pressure Injury Prevention and Treatment: The Importance of Relevant, Reliable, and Contextualised Data

Prof. Dimitri Beeckman

Örebro University, Sweden
Ghent University, Belgium

President
European Wound Management Association



Global, regional and national burden of decubitus ulcers in 204 countries and territories from 1990 to 2021: a systematic analysis based on the global burden of disease study 2021

Shenyue Zhang¹, Guoxing Wei^{2,3}, Liu Han⁴, Weibing Zhong⁵, Zhenan Lu^{6*} and Zehao Niu^{1,6*}

¹Department of Biomedical Sciences, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Kowloon, Hong Kong SAR, China; ²Department of Pediatrics, The 63 Affiliated Hospital of Shandong Medical University, Jinan, China; ³Department of Burns and Plastic Surgery, The 83 Affiliated Hospital of Shandong Medical University, Jinan, China; ⁴Department of Plastic Surgery, Southern Hospital, Tsinghua Medical University, Beijing, China; ⁵Department of Chongqing, China; ⁶Key Laboratory of Tissue Repair and Regeneration (Wuhan) (Wuhan University, Ministry of Education, Hubei International Soft Science Technological Cooperation Base of Tissue Regeneration, Materials Application, Wuhan, Hubei University, Wuhan, China)

Background: Decubitus ulcers, also known as pressure ulcers, pose a significant public health challenge due to their substantial impact on morbidity, mortality, and healthcare expenditures.

Methods: The number and age-standardized rates (ASRs) of prevalence, death, disability adjusted life-year (DALY), years of life lost (YLL), and years lived with disability (YLD) at the global, regional, and national levels were acquired from the GBD 2021 database. Trends were evaluated based on the estimated average percentage change (EAPC) of ASRs. Additionally, data were stratified by socio-demographic index (SDI) quantiles, regions, countries, territories, and age groups.

Results: The total number of decubitus ulcer cases increased from 503,419 in 1990 to 645,568 in 2021. The global ASR of prevalence decreased slightly from 8.25 to 7.92 per 100,000 persons, with most cases occurring in individuals 60 and older. Deaths due to decubitus ulcers rose from 16,622 in 1990 to 32,000 in 2021, while the global ASR of death declined from 0.53 to 0.46 per 100,000 persons. DALY due to decubitus ulcers increased, exhibiting significant growth across regions and age groups. A higher SDI was correlated with increased prevalence (IR = 0.465, $p < 0.001$) and YLD (IR = 0.495, $p < 0.001$). Conversely, a higher SDI was correlated with lower ASRs of death (IR = -0.329, $p < 0.001$) and DALY (IR = -0.398, $p < 0.001$), and YLL (IR = -0.445, $p < 0.001$).

Conclusion: The global burden of decubitus ulcers has risen, with notable regional and age-related disparities. This study offers valuable insights for policymakers to optimize healthcare strategies and mitigate the public health impact of decubitus ulcers.

KEYWORDS

decubitus ulcers, pressure ulcers, burden, trends, systematic analysis

Global Public Health Context

- **Global Public Health Context (Zhang et al., 2025)**
 - 1990 → 2021: cases rose from 300k → 646k; deaths from 16k → 37k.
 - Disability burden (DALYs) doubled: 409k → 804k.
 - Prevalence ~ 8 per 100k population, mostly in those 60+ years.
 - Aging populations drive rising absolute burden despite stable/decreasing age-adjusted rates.

Check for updates

OPEN ACCESS

EDITED BY
Chao, Kaimin,
Nankai University (Nankai), United States

REVIEWED BY
Ananya Kulkarni,
National Institute of Allergy and Infectious
Diseases (NIH), United States
Rashed Wazwani,
National Institute of Health (NIH),
United States

*CORRESPONDENCE
Zhenan Lu
lu_zhenan@cityu.edu.hk
Zehao Niu
niu_zehao@cityu.edu.hk

RECEIVED 22 October 2024
ACCEPTED 14 February 2025
PUBLISHED 26 February 2025

CITATION

Zhang S, Wei G, Han L, Zhong W, Lu Z and Niu Z (2025) Global, regional, and national burden of decubitus ulcers in 204 countries and territories from 1990 to 2021: a systematic analysis based on the global burden of disease study 2021.
Front. Public Health 13:1494229.
doi: 10.3389/fpubh.2025.1494229

COPYRIGHT

© 2025 Zhang, Wei, Han, Zhong, Lu and Niu. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Trends, risk factors and policy implications

- **Trends (1990-2021)**
 - Global prevalence rate stable (-0.02% change), but absolute numbers increased.
- **Disparities**
 - High-SDI regions (e.g., Western Europe, North America):
 - Higher reported prevalence (better detection, older populations).
 - Lower mortality and DALYs (better prevention and treatment).
 - Low-SDI regions: fewer reported cases but higher death & disability rates.

Why talk about health economics?

High proportion of healthcare spending

- In the UK, treating pressure ulcers costs between £1.4 billion and £2.1 billion annually, equating to 4 % of NHS expenditure.
- In Spain, annual cost estimated at around €461 million, about 5 % of the healthcare budget.
- Across OECD countries, direct costs from unsafe care (which includes pressure ulcers) are estimated at 2 - 4 % of total health expenditure.



Hidden costs



- Out-of-court settlements: typically £ 20 - 30k, but can reach £ 1 - 3M in severe cases.
- NHS spending since 2013: £ 168M on pressure ulcer litigation (≈£66k/claim).
- Total claims (incl. damages & legal costs): approx. £ 322M (NHS Resolution).

Hidden costs

- Reputational damage from litigation and media exposure
- Extended hospital stays reduce bed availability and efficiency
- Patient/family burden: pain, anxiety, social isolation



Quality of life: the reality behind the economics

A 2025 systematic review included 22 studies (12 quantitative, 9 qualitative, 1 mixed-methods).

- Pressure injuries were associated with poorer HRQoL across four major domains:
 - Symptoms: particularly pain and discomfort
 - Physical function: mobility, activity and independence
 - Psychological wellbeing: anxiety, frustration, loss of dignity
 - Social functioning : isolation and restricted participation
- If quality of life is absent from the economic model, an important part of the benefit of prevention and effective treatment disappears.

**Two
takeaways
so far ...**





1

Pressure ulcers cause
avoidable harm with high
human and financial costs -
prevention is both a moral and
economic imperative

2

Economic data on pressure ulcers is inconsistent and incomplete, underestimating true costs, especially indirect ones, making prevention benefits harder to prove.

Prevention vs treatment: a clinical trial example

- Belgian KCE RCT & economic evaluation (2023)
- Design: 1,633 at-risk hospitalized patients, 8 hospitals.
- Intervention: Silicone adhesive multilayer foam dressings (sacrum, heels, trochanter) + standard care vs standard care alone.
- Clinical outcomes:
 - New pressure ulcers (Cat. II+): 4.0% (dressing) vs 6.3% (standard care) → 36% risk reduction (RR 0.64, $p=0.04$).
 - Strongest effect at sacrum (risk reduced by 41%).
 - No significant effect on heels; very few trochanter ulcers.



The policy dilemma



Limited budgets force tough choices.



New technology often looks more attractive.



Prevention programmes are less visible but highly impactful



Without strong health-economic evidence, prevention often loses out to flashier investments.

The health- economics reality

Table 27 – Overview of costs and consequences sacrum PU prevention with silicone adhesive multilayer foam dressings

Variable	Value	More Information in part
Cost prevention:		
- Dressings (average use: 3)	€30 (~€27**)	6.2.2.1
- Time (3 times 2 minutes)	€4.52	
ARR PU (NNT)	2% (50)	6.2.1.1
Total investment cost per PU avoided: €1726* (~€1576**)		
Distribution PUs	Cat. II: 65.4% Cat. III/IV: 34.6%	6.2.1.1
QoL	Potentially smaller Improvement in QoL in patients with PUs	5.3.1
Cost PU treatment under assumption of no increase in LoS for PU cat. II.	€212	6.2.2.2
Cost PU treatment under assumption of an increase in LoS of 5 days for PU cat. III/IV.	€4313***	6.2.2.2
Total savings under the applied assumptions: €1631****		

ARR: absolute risk reduction; Cat.: category; NNT: number needed to treat; PU: pressure ulcer; QoL: quality of life.

* $(€30 + €4.52) \times 50$ (NNT) = €1726.

** This is the result if a cost of about €9 per dressing is applied.

*** $(€3907 + €4719)/2 = €4313$.

**** $(65.4\% \times €212) + (34.6\% \times €4313) = €1631$.

- Costs: Dressings add upfront costs (~13 dressings/patient, avg. use per trial), but prevention may avoid expensive Cat. III-IV ulcers. Break-even possible if severe ulcers are prevented.
- Claim
 - Prevention is cost-saving and ethically imperative: Investing in prophylactic measures (e.g., silicone multilayer foam dressings on sacrum) can reduce ulcer incidence, avoid high treatment and litigation costs, protect hospital reputation, and lessen patient/family suffering.

The bigger picture

- A PI prevented reduces:
 - Staff burnout (less repetitive wound care)
 - Material waste and carbon emissions.
 - Overall financial strain on health systems.
- Sustainability = economic + environmental + workforce well-being.



Two more
takeaways ...





1

OECD notes that promising digital prevention tools lack solid evidence on costs, benefits, and ROI, particularly in patient safety.

2

Policy inertia and short-term thinking drive underinvestment in prevention, despite it being 3-4 times more cost-effective than treatment.

Current evidence: a patchwork

Many studies - but methodologically diverse and hard to compare.

Systematic review found large variations in cost estimates:

- Treatment cost per patient per day ranges from €1.71 to €470.49, depending on the setting.
- Prevention costs ranged from €2.65 to €87.57.



Current evidence: a patchwork

UK study variations:

- One UK estimate: £1,214 (Grade 1) to £14,108 (Grade 4) per ulcer
- Another estimate cited total NHS annual cost at £1.4-£2.1 billion (~4% of budget)
- Wide-ranging figures reflect conflicting inclusion of cost components, e.g., productivity vs. direct care costs.



Why foundations matter

- Prevention is consistently shown to be cost-effective: prevention bundles save thousands per patient and reduce incidence by >70%.
- Yet prevention remains underfunded because:
- Short-term cost models ignore long-term savings (e.g., avoided complications, reduced hospital stays).
- Indirect benefits (quality of life, productivity gains, caregiver relief) are rarely included in models.



More?





1

Decision-makers favour visible,
high-tech investments over
“quiet savings” from
prevention

2

Weak data foundations lead to underinvestment in safety and prevention, despite evidence of high returns (OECD, 2022)

The three building blocks

Relevance: Does the data capture what really matters?

- Many studies only measure “visible” costs = underestimate the true burden.
- Spain: Pressure ulcer care ~€461 million/year, > 50% from hospital stay length (not just dressings/materials).
- Canada: Excluding quality-of-life impacts underestimated total burden by ~30%.



The three building blocks

Relevance: Does the data capture what really matters?



Direct Costs

Staff time and nursing workload
Support surfaces and equipment
Prophylactic dressings
Skin care products
Monitoring technologies
Organisational infrastructure
Protocol development
Auditing systems
Nutritional support
Surgical interventions

Indirect Costs

Prolonged hospital stays
Readmissions
Reduced patient mobility
Loss of productivity
Long-term disability
Caregiver burden
Diminished quality of life
Social isolation / stigma
Psychological distress
Early mortality

The three building blocks

Relevance: Does the data capture what really matters?

- Spain (Soldevilla Agreda, 2007): Main direct prevention costs came from special mattresses, cushions, and nursing time.
- Germany (Rexroth et al., 2015): Preventive dressings and staff time were the largest cost drivers in ICU prevention bundles.
- US (Padula et al., 2019): Workforce costs and capital equipment (beds, mattresses) accounted for the bulk of prevention expenses.



The three building blocks

Relevance: Does the data capture what really matters?

- US Medicare data: Surgical closure of stage III/IV pressure ulcers costs \$124,000+ per patient on average.
- UK NHS data: Flap surgery alone for a pressure ulcer estimated at £11,000-£15,000, excluding long-term follow-up.
- Recurrence rates post-surgery can be as high as 28-40%, adding repeat costs..



The three building blocks

Reliability: Are the data accurate and comparable?

- Study design and definitions vary → inconsistent estimates.
- Netherlands vs. Germany: Prevention costs ranged from €2.65/day to €87/day, same interventions but different costing frameworks.
- Multicentre EU study: Prevalence estimates varied 5 - 25% across sites just from differences in data collection methods.



The three building blocks

Reliability: Are the data accurate and comparable?

- Registries: Large-scale, centralised data improve comparability.
- EHRs (Electronic Health Records): Enable continuous, real-world data collection.
- Standardised definitions: Reduce variation and ensure consistency across studies.



The three building blocks

Context: Do the data apply to the local setting?

- Data often transplanted without adaptation.
- US: Severe pressure ulcer treatment cost >\$70,000 per case.
- Eastern Europe (Czech Republic): Median cost €678-€929 per case (different wage structures/system).



The three building blocks

Context: Do the data apply to the local setting?

- Time horizons: acute episode vs. long-term view.
- In Spain, 6-month horizon = prevention costly; 2-year horizon = prevention saves millions.




The three building blocks

Context: Do the data apply to the local setting?

- Health systems and wages: In Finland, higher nurse wages raise prevention costs, but outcomes still favour prevention long term.
- Japan: Costs dominated by nursing-home care, unlike Western Europe where hospitals dominate.

Another 3 ...





1

Relevant data = hospital stay +
complications + QOL + caregiver
time.



2

Without reliable, standardized methods, cross-study comparisons are misleading.



3

Context matters: what is cost-effective in one setting/region/country may not be in another.

From data to decisions

- Strong data → robust models → better policies
- Pressure ulcer prevention still lacks a unified economic evidence base.
- Like OECD work on diabetes, a standardised framework could transform pressure ulcer prevention policy.



🔗 Definition and comparability

Diabetes hospital admission data are based on the sum of three indicators: admissions for complications and for uncontrolled diabetes without complications. The indicator is defined as admissions with a primary diagnosis of diabetes among people aged 15 years and over. Lower extremity amputation in adults with diabetes is defined as the number of discharges over per 100 000 population. Rates for these indicators have been age-standardised to the

Differences in data definition, diagnostic and coding practices and indicator calculation may affect comparability of data. For example, in many countries diabetes is coded as a secondary diagnosis, while in other countries it is coded as a primary diagnosis. Differences in data coverage of the national hospitalisation data also influence indicator rates.

The denominator of people with diabetes who are prescribed recommended antihypertensive medication is defined as people with diabetes (i.e. who are long-term users of glucose-regulating medication) who have been prescribed per year from a range of medications often used in the management of hypertension. The numerator is the number of people who have one or more prescriptions of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.

References

WHO (2021), *IDF Diabetes Atlas 2021*, International Diabetes Federation,



Take-Home Messages

- HAPIs are expensive and wasteful.
- Prevention is cost-saving and sustainable.
- Investments in prevention → better care, lower costs, smaller footprint.
- Prevention = value-based healthcare in action.
- Invest early to save later.

References

- Bennett G, Dealey C, Posnett J. *The cost of pressure ulcers in the UK*. Age Ageing. 2004;33(3):230-235.
- Dealey C, Posnett J, Walker A. *The cost of pressure ulcers in the United Kingdom*. J Wound Care. 2012;21(6):261-266.
- Demarré L, Van Lancker A, Van Hecke A, et al. *The cost of prevention and treatment of pressure ulcers: a systematic review*. Int J Nurs Stud. 2015;52(11):1754-1774.
- Roubik V, et al. *Comprehensive cost-of-illness analysis of pressure ulcer treatment: A real-world study at a Czech university hospital*. (Preprint, 2025).
- Padula WV, et al. *Value of hospital resources for effective pressure injury prevention: a cost-effectiveness analysis*. BMJ Qual Saf. 2019;28(2):132-141.

References

- Padula WV, Delarmente BA. *The national cost of hospital-acquired pressure injuries in the United States*. Int Wound J. 2019;16(3):634-640.
- Padula WV, Pronovost PJ, Makic MBF, Wald HL. *Value of hospital resources for effective pressure injury prevention: a cost-effectiveness analysis*. BMJ Qual Saf. 2019;28(2):132-141.
- OECD. *The economics of patient safety: Strengthening a value-based approach to reducing patient harm at national level*. OECD Health Working Paper No. 96, 2022.
- Soldevilla Agreda JJ, Torra i Bou JE, Verdú Soriano J, et al. *The cost of treating pressure ulcers in Spain*. Gerokomos. 2007;18(3):162-170.
- Chan B, Ieraci L, Parsons D, et al. *Economic impact of pressure ulcers in Canada*. Healthc Manage Forum. 2013;26(4):199-204.

References

- Vanderwee K, Clark M, Dealey C, Gunningberg L, Defloor T. *Pressure ulcer prevalence in Europe: a pilot study*. J Adv Nurs. 2007;58(5):410-418.
- Vanderwee K, Defloor T, Beeckman D, et al. *Assessing the reliability of two pressure ulcer classification systems: a multicentre study*. Int J Nurs Stud. 2007;44(2):285-292.
- Keys KA, Daniali LN, Warner KJ, Mathes DW. *Multivariate predictors of failure after flap coverage of pressure ulcers*. Plast Reconstr Surg. 2010;125(6):1725-1734.
- Sanada H, et al. *Epidemiology and cost analysis of pressure ulcers in Japan*. Wound Repair Regen. 2008;16(2):147-153.

References

- Rexroth U, et al. *Prevention of pressure ulcers in intensive care patients: Economic evaluation of preventive dressings in Germany*. J Tissue Viability. 2015;24(4):123-130.
- McInnes E, Jammali-Blasi A, Bell-Syer SE, Dumville JC, Middleton V, Cullum N. *Support surfaces for pressure ulcer prevention*. Cochrane Database Syst Rev. 2015;(9):CD001735.
- Tayyib N, Coyer F, Lewis P. *Implementing a pressure ulcer prevention bundle in adult intensive care*. Worldviews Evid Based Nurs. 2015;12(4):241-247.
- Nixon J, Nelson EA, Cranny G, Iglesias CP, Hawkins K, Cullum NA. *Pressure relieving support surfaces: cost-effectiveness and outcomes in a randomized controlled trial*. Health Technol Assess. 2006;10(22).

References



- Pham B, Stern A, Chen W, Sander B, John-Baptiste A, Thein HH, et al.
Preventing pressure ulcers in long-term care: a cost-effectiveness analysis.
Arch Intern Med. 2011;171(20):1839-1847.



Mölnlycke®